MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications Berlin, Germany, and Nevada, USA, June 7, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, o [ … ]

MagForce Announces Additional Supportive Data from Stage 2a of its Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System - Further analysis of the Stage 2a results confirm positive initial findings published in February of this year - treatment-related side effects remained min [ … ]

MagForce AG Successfully Completes Private Placement of New Shares - Placement of 1.165 million shares or 4.2 percent of the share capital - Gross proceeds of approx. EUR 4.7 million Berlin and Nevada, December 15, 2020 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedici [ … ]

MagForce AG Announces Opening of New NanoTherm Treatment Center for Brain Tumor Patients at Mühlhausen Hufeland Clinic in Thuringia, Germany All audits of the new NanoTherm treatment center at the Mühlhausen Hufeland Clinic have been completed, first patients are anticipated to be treated in December 2020 The center is managed by PD Dr. Johannes  [ … ]

MagForce AG Publishes Financial Results for the First Half of 2020 and Operative Highlights   - Very significant increase in European patient inquiries for NanoTherm therapy system for the treatment of glioblastomas - U.S. focal prostate cancer treatment study: positive findings of Stage 1 confirmed during current Stage - positive treatment resul [ … ]

DGAP-Media / 20.10.2020 / 09:50 MagForce AG: 'NanoTherm School' successfully enters the third round with 'Module B - Part II' - MagForce successfully hosted the third session of the practice-oriented, unique and multifaceted application training series for the use of the NanoTherm therapy system for the treatment of glioblastoma. - The Nan [ … ]

MagForce AG Publishes Shareholder Letter Europe: Continued significantly increased numbers of brain tumor treatments USA: Treatments of patients in current stage of the prostate cancer trial with streamlined protocol so far show only minimal treatment-related side effects Berlin, Germany, and Nevada, USA, September 21, 2020 - MagForce AG (Frankf [ … ]

MagForce AG announces positive results of 2020 Annual General Meeting Berlin, Germany, and Nevada, USA, August 13, 2020 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, held its Annual General Meeting today in a virtual setting. The Annual General M [ … ]